|
PFKM expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.12010000000262E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.67510000040438E-07 |
| Normal-vs-Stage2 |
3.938200E-01 |
| Normal-vs-Stage3 |
3.72670000414743E-08 |
| Normal-vs-Stage4 |
1.57470000372584E-08 |
| Stage1-vs-Stage2 |
5.168600E-04 |
| Stage1-vs-Stage3 |
1.905350E-01 |
| Stage1-vs-Stage4 |
4.729700E-02 |
| Stage2-vs-Stage3 |
8.37880000000846E-05 |
| Stage2-vs-Stage4 |
2.32569999999432E-05 |
| Stage3-vs-Stage4 |
5.157800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.17759999529454E-08 |
| Normal-vs-AfricanAmerican |
2.837200E-03 |
| Normal-vs-Asian |
2.049300E-04 |
| Caucasian-vs-AfricanAmerican |
3.408600E-01 |
| Caucasian-vs-Asian |
8.649800E-01 |
| AfricanAmerican-vs-Asian |
5.725000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.29480000005322E-06 |
| Normal-vs-Female |
7.54320000018183E-07 |
| Male-vs-Female |
5.613200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.17269999664072E-08 |
| Normal-vs-Age(41-60Yrs) |
2.52400000000375E-06 |
| Normal-vs-Age(61-80Yrs) |
2.069500E-02 |
| Normal-vs-Age(81-100Yrs) |
4.104000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.340200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.705800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.162000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.086820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.943400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.923000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.33209999999496E-05 |
| Classical-VS-Follicular |
6.3472999967118E-08 |
| Classical-VS-Other |
9.817400E-01 |
| Classical-VS-Normal |
1.5546000042832E-09 |
| Tall-VS-Follicular |
3.22264437357944E-12 |
| Tall-VS-Other |
2.960400E-01 |
| Tall-VS-Normal |
2.05391259555654E-14 |
| Follicular-VS-Other |
9.072500E-02 |
| Follicular-VS-Normal |
4.442800E-01 |
| Other-VS-Normal |
1.476280E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.575100E-04 |
| Normal-vs-N1 |
7.38631378283117E-13 |
| N0-vs-N1 |
3.57679999951621E-07 |
|
|
